
Please try another search
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Eugen Steiner | 69 | 2017 | Independent Chairman |
Mikael Smedeby | 56 | 2018 | Independent Director |
Kaj Blennow | - | - | Member of Scientific Advisory Board |
Charlotta Ljungqvist | 63 | 2021 | Independent Director |
Staffan Pauli | - | - | Member of Scientific Advisory Board |
Martin Ingelsson | - | - | Member of Scientific Board |
Hans Wigzell | 86 | - | Member of Scientific Advisory Board |
Ken Marek | - | - | Member of Scientific Advisory Board |
Marie Cecilia Edström | 58 | 2023 | Independent Director |
Anna-Lena Engwall | 53 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review